Clinical trial · Observational
Detection of Bloodstream Pathogens in Hematological Malignancies
NCT03896880CI-TRIAL-00066469completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
* To identify the common bacterial and fungal species causing fungemia and bacteremia in hematological malignancies. * To identify sensitivity pattern for causative microbes. * Compare culture on ordinary media with Vitek2 (automated microbial identification system) and multiplex polymerase chain reaction (PCR )
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bloodstream Infection | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anti fungal susceptibility testing or antibiotic susceptibility testing | Other | — | UNRESOLVED |
| blood culture | Diagnostic Test | — | UNRESOLVED |
| Identification of the isolated organism by multiplex PCR | Other | — | UNRESOLVED |
| phenotypic identification methods of the isolated organism by Vitek2 (BioMerieux,France) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- blood culture positive
- description
- hematological malignancy patients with positive blood culture
- interventionNames
- Diagnostic Test: blood culture
- Other: Anti fungal susceptibility testing or antibiotic susceptibility testing
- Other: phenotypic identification methods of the isolated organism by Vitek2 (BioMerieux,France)
- Other: Identification of the isolated organism by multiplex PCR
Primary outcomes (4)
- measure
- identify pathogens in positive blood culture in hematological malignancies patients
- timeFrame
- 1 year
- description
- Examine blood culture to diagnose different species of pathogens including bacteria and fungi responsible for bloodstream infection in hematological malignancies patients.
- measure
- Antimicrobial susceptibility testing and drug resistance
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * hematological malignancy patients on chemotherapy associated with fever Exclusion Criteria: * Age below 18 years old
References
Publications (4)
- BACKGROUNDSalomao R, Diament D, Rigatto O, Gomes B, Silva E, Carvalho NB, Machado FR. Guidelines for the treatment of severe sepsis and septic shock - management of the infectious agent - source control and antimicrobial treatment. Rev Bras Ter Intensiva. 2011 Jun;23(2):145-57. English, Portuguese. PMID 25299714
- BACKGROUNDGedik H, Simsek F, Kanturk A, Yildirmak T, Arica D, Aydin D, Demirel N, Yokus O. Bloodstream infections in patients with hematological malignancies: which is more fatal - cancer or resistant pathogens? Ther Clin Risk Manag. 2014 Sep 17;10:743-52. doi: 10.2147/TCRM.S68450. eCollection 2014. PMID 25258539
- BACKGROUNDYadegarynia D, Tarrand J, Raad I, Rolston K. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis. 2003 Oct 15;37(8):1144-5. doi: 10.1086/378305. No abstract available. PMID 14523785
- BACKGROUNDBrown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012 Dec 19;4(165):165rv13. doi: 10.1126/scitranslmed.3004404. PMID 23253612